Pandanus Associates Inc. bought 474,000 shares of MEDLIVE stock at an average of HKD 7.915 per share on August 12, 2026, involving about HKD 3.75 million.
Prior to the acquisition, Pandanus Associates Inc.'s long position in MEDLIVE was 58.85 million shares, representing 7.95%; following the acquisition, the holding changed to 59.33 million shares, with the long position ratio rising to 8.01%.